Tyvaso Approval History

• FDA approved: Yes (First approved July 30th, 2009)
• Brand name: Tyvaso
• Generic name: treprostinil
• Company: United Therapeutics Corporation
• Treatment for: Pulmonary Arterial Hypertension

Tyvaso (treprostinil) is an inhaled prostanoid analogue indicated for the treatment of pulmonary arterial hypertension.

FDA Approval History for Tyvaso

Date	Article
Jul 30, 2009	FDA Approves Tyvaso (treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
Apr 28, 2009	U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months
Mar 16, 2009	United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
Sep  3, 2008	Inhaled Treprostinil New Drug Application Filed by FDA
Jun 30, 2008	New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

See also...

Tyvaso (treprostinil) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.